Data Collection
BLIND
Data were collected between February 2021 and March 2022. The oncologist informed eligible patients with GC about the MGCS program. Patients with GC who expressed an interest in this study were approached by a member of the research team to provide more detailed information. After signing the paper consent form, all participants completed paper-based demographic and baseline health outcomes questionnaires before randomization (T0). Participants were notified of their group allocations in the trial. Following the protocol of the participating hospitals, patients with GC received 4-8 cycles of chemotherapy (3 weeks/cycle). Chemotherapy was usually completed within 24 weeks. Participants in both groups completed the paper questionnaires at 12 (T1) and 24 weeks (T2). The researchers who collected questionnaires were not blind to group allocation. If the participants did not return to the hospital at either time point, a researcher contacted them by phone and mailed them the questionnaires.